New combo treatment for Rock-Hard arteries shows promise in clinical trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years, able to understand the study purpose and voluntarily sign written informed consent * Coronary angiography confirmed severe calcified lesions (Mintz classification ≥Grade 2), with IVUS unable to pass or showing calcification grade ≥2 * Native coronary artery lesion * Target vessel diameter 2.5-4.0mm * Lesion length ≤30mm, suitable for rotational atherectomy * Clinical indication for PCI: Ischemic cardiomyopathy confirmed by functional testing (e.g., myocardial nuclear scan); Clinical presentation of stable or unstable angina with clear PCI indication * Planned rotational atherectomy as initial calcium modification technique * After rotational atherectomy (burr diameter ≤1.5mm), IVUS shows calcification grade still ≥2, or \<2 but 2.5mm non-compliant balloon cannot achieve adequate expansion at nominal pressure * Informed consent signed and agreement to participate in clinical trial * Able to comply with treatment and complete follow-up Exclusion Criteria: * Acute myocardial infarction (AMI) within 7 days, as condition may be unstable and increase periprocedural complication risk * Target vessel characteristics: Target vessel with thrombus formation, may increase intraoperative embolism risk; Target vessel with chronic total occlusion (CTO), unable to be treated by rotational atherectomy and calcium modification techniques; Target lesion is in-stent restenosis; Target lesion located in coronary artery bypass graft * Severe heart failure: left ventricular ejection fraction \<30%, poor tolerance to PCI surgery, may increase perioperative mortality risk * Previous treatment history: previous stent implantation or rotational atherectomy in the same target vessel, as complex lesion structure or confounding treatment effects may exist * Special medical history: Known contrast allergy or severe bleeding tendency (such as active gastrointestinal bleeding), may be unable to tolerate PCI surgery; Patients with other serious comorbidities, expected to be unable to complete 12-month follow-up (such as life expectancy \<12 months) * Pregnancy or lactation: pregnant or lactating women, as intraoperative radiation and drug effects may adversely affect mother and child * Participation in other clinical trials: patients simultaneously participating in other interventional clinical trials, to avoid mutual influence of different trial intervention measures